SEARCH

SEARCH BY CITATION

References

  • Alexanian, R., Barlogie, B., Dixon, D. (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of Internal Medicine, 150, 16931695.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 9197.
  • Baldini, L., Radaelli, F., Chiorboli, O., Fumagalli, S., Cro, L., Segala, M., Cesana, B.M., Polli, E.E., Maiolo, A.T. (1991) No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer, 68, 6267.
  • Ballester, O.F., Tummala, R., Janssen, W.E., Fields, K.K., Hiemenz, J.W., Goldstein, S.C., Perkins, J.B., Sullivan, D.M., Rosen, R., Sackstein, R., Zorsky, P., Saez, R., Elfenbein, G.J. (1997) High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplantation, 20, 653656.
  • Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B., Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 5565.
  • Blade, J., Fernandez-Llama, P., Bosch, F., Montoliu, J., Lens, X.M., Montoto, S., Cases, A., Darnell, A., Rozman, C., Montserrat, E. (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine, 158, 18891893.
  • Cavo, M., Baccarani, M., Galieni, P., Gobbi, M., Tura, S. (1986) Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients. Nouvelle Review of French Hematology, 28, 147152.
  • Chang, S.Y., Alberts, D.S., Farquhar, D., Melnick, L.R., Watson, P.I., Salmon, S.E. (1978) Hydrolysis and protein binding of melphalan. Journal of Pharmacological Science, 67, 682684.
  • Cohen, D.J., Sherman, W.H., Osserman, E.F., Appel, G.B. (1984) Acute renal failure in patients with multiple myeloma. American Journal of Medicine, 76, 247256.
  • Confalonieri, R., Barbiano di Belgiojoso, G., Banfi, G., Ferrario, F., Bertani, T., Pozzi, C., Casanova, S., Lupo, A., De Ferrari, G., Minetti, L. (1988) Light chain nephropathy: histological and clinical aspects in 15 cases. Nephrology, Dialysis and Transplantation, 3, 150156.
  • Cosio, F.G., Pence, T.V., Shapiro, F.L., Kjellstrand, C.M. (1981) Severe renal failure in multiple myeloma. Clinical Nephrology, 15, 206210.
  • DeFronzo, R.A., Cooke, C.R., Wright, J.R., Humphrey, R.L. (1978) Renal function in patients with multiple myeloma. Medicine (Baltimore), 57, 151166.
  • Desikan, K.R., Tricot, G., Munshi, N.C., Anaissie, E., Spoon, D., Fassas, A., Toor, A., Zangari, M., Badros, A., Morris, C., Vesole, D.H., Siegel, D., Jagannath, S., Barlogie, B. (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. British Journal of Haematology, 112, 242247.DOI: 10.1046/j.1365-2141.2001.02498.x
  • Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P., Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 40084010.
  • Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842854.
  • Durie, B.G., Dixon, D.O., Carter, S., Stephens, R., Rivkin, S., Bonnet, J., Salmon, S.E., Dabich, L., Files, J.C., Costanzi, J.J. (1986) Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 4, 12271237.
  • Gera, S., Musch, E., Osterheld, H.K., Loos, U. (1989) Relevance of hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemotherapy and Pharmacology, 23, 7680.
  • Gouyette, A., Hartmann, O., Pico, J.L. (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemotherapy and Pharmacology, 16, 184189.
  • Herget-Rosenthal, S., Uppenkamp, M., Beelen, D., Kohl, D., Kribben, A. (2000) Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation. Nephron, 84, 136141.
  • Iggo, N., Palmer, A.B., Severn, A., Trafford, J.A., Mufti, G.J., Taube, D., Parsons, V. (1989) Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Quarterly Journal of Medicine, 73, 903910.
  • Innes, A., Cuthbert, R.J., Russell, N.H., Morgan, A.G., Burden, R.P. (1994) Intensive treatment of renal failure in patients with myeloma. Clinical Laboratory and Haematology, 16, 149156.
  • Irish, A.B., Winearls, C.G., Littlewood, T. (1997) Presentation and survival of patients with severe renal failure and myeloma. Quarterly Medical Journal, 90, 773780.
  • Johnson, W.J., Kyle, R.A., Pineda, A.A., O'Brien, P.C., Holley, K.E. (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Archives of Internal Medicine, 150, 863869.
  • Knudsen, L.M., Hjorth, M., Hippe, E. (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. European Journal of Haematology, 65, 175181.
  • Korzets, A., Tam, F., Russell, G., Feehally, J., Walls, J. (1990) The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. American Journal of Kidney Disease, 16, 216223.
  • Krejci, M., Doubek, M., Adam, Z., Hajek, R., Vorlicek, J., Mayer, J. (1997) [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency]. Vnitr Lek, 43, 756758.
  • Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I.M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I., Rodjer, S. (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood, 95, 711.
  • Magee, C., Vella, J.P., Tormey, W.P., Walshe, J.J. (1998) Multiple myeloma and renal failure: one center's experience. Renal Failure, 20, 597606.
  • Misiani, R., Tiraboschi, G., Mingardi, G., Mecca, G. (1987) Management of myeloma kidney: an anti-light-chain approach. American Journal of Kidney Disease, 10, 2833.
  • Montseny, J.J., Kleinknecht, D., Meyrier, A., Vanhille, P., Simon, P., Pruna, A., Eladari, D. (1998) Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrology, Dialysis and Transplantation, 13, 14381445.
  • Medical Research Council report (1984) Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. British Medical Journal (Clinical Residents edition), 288, 14111416.
  • Pecherstorfer, M., Zimmer-Roth, I., Weidinger, S., Irsigler, K., Halbmayer, W.M., Ulrich, W., Fischer, M., Baumgartner, G. (1994) High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure. Clinical Investigation, 72, 522525.
  • Powles, R., Raje, N., Milan, S., Millar, B., Shepherd, V., Mehta, J., Singhal, S., Kulkarni, S., Viner, C., Gore, M., Cunningham, D., Treleaven, J. (1997) Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplantation, 20, 435443.
  • Pozzi, C., Pasquali, S., Donini, U., Casanova, S., Banfi, G., Tiraboschi, G., Furci, L., Porri, M.T., Ravelli, M., Lupo, A., Schena, F.P., Brunati, C., Imbasiati, E., Locatelli, F. (1987) Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clinical Nephrology, 28, 19.
  • Rebibou, J.M., Caillot, D., Casasnovas, R.O., Tanter, Y., Maillard, N., Solary, E., Rifle, G., Guy, H. (1997) Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplantation, 20, 6365.
  • Reiter, E., Kalhs, P., Keil, F., Rabitsch, W., Gisslinger, H., Mayer, G., Worel, N., Lechner, K., Greinix, H.T. (1999) Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Annals of Hematology, 78, 189191.DOI: 10.1007/s002770050499
  • Rota, S., Mougenot, B., Baudouin, B., De Meyer-Brasseur, M., Lemaitre, V., Michel, C., Mignon, F., Rondeau, E., Vanhille, P., Verroust, P., Konco, P. (1987) Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore), 66, 126137.
  • Samuels, B.L. & Bitran, J.D. (1995) High-dose intravenous melphalan: a review. Journal of Clinical Oncology, 13, 17861799.
  • Schuh, A., Dandridge, J., Haydon, P., Littlewood, T.J. (1999) Encephalopathy complicating high-dose melphalan. Bone Marrow Transplantation, 24, 11411143.
  • Tapson, J.S., Mansy, H., Wilkinson, R. (1988) End-stage renal failure due to multiple myeloma – poor survival on peritoneal dialysis. International Journal of Artificial Organs, 11, 3942.
  • Torra, R., Blade, J., Cases, A., Lopez-Pedret, J., Montserrat, E., Rozman, C., Revert, L. (1995) Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. British Journal of Haematology, 91, 854859.
  • Tosi, P., Zamagni, E., Ronconi, S., Benni, M., Motta, M.R., Rizzi, S., Tura, S., Cavo, M. (2000) Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia, 14, 13101313.
  • Tranchand, B., Biron, P., Mercatello, A., Philip, T., Ardiet, C. (1988) [Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. Cancer Bulletin, 75, 291296.
  • Tricot, G., Alberts, D.S., Johnson, C., Roe, D.J., Dorr, R.T., Bracy, D., Vesole, D.H., Jagannath, S., Meyers, R., Barlogie, B. (1996) Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clinical Cancer Research, 2, 947952.
  • Zervas, K., Pouli, A., Gregoraki, B., Anagnostopoulos, N., Dimopoulos, M.A., Bourantas, K., Tzilianos, M., Barbarousi, D., Venetis, E., Vyniou, N., Maniatis, A. (2001) Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP), interferon-alpha with melphalan, prednisone (MP), interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group. European Journal of Haematology, 66, 1823.DOI: 10.1034/j.1600-0609.2001.00285.x